Table 1.
Baseline demographic and clinical characteristics.
| Characteristic | Safety population (n = 81) |
|---|---|
| Age, years | 71.5 ± 8.6 |
| Gender | |
| Male, n (%) | 44 (54.3) |
| Female, n (%) | 37 (45.7) |
| Time since first diagnosis, years | 5.6 ± 5.2 |
| Hoehn and Yahr stage, n (%) | |
| I | 17 (21) |
| II | 33 (40.7) |
| III | 27 (33.3) |
| IV | 4 (4.9) |
| PDSS-2 total score | 23.3 ± 8.8 |
| PDQ-8 score | 24.2 ± 19.2 |
| VAS-pain score | 3.2 ± 2.6 |
| CGI-S score | 3.7 ± 0.6 |
| Concomitant dopaminergic medication, n (%) | 81 (100) |
| Levodopa preparations | 70 (86.4) |
| Dopamine agonists | 32 (39.5) |
| MAO-B inhibitors | 31 (38.3) |
| Entacapone | 2 (2.5) |
| Major complaints of patients who received nocturnal rotigotine, n (%) | |
| Difficulty maintaining sleep | 71 (87.7) |
| Nocturia | 56 (69.1) |
| Difficulty falling asleep | 46 (56.8) |
| Nocturnal/early morning akinesia | 42 (51.9) |
| Restless legs | 42 (51.9) |
| Vivid dreams | 41 (50.6) |
| Pain in arms and legs | 31 (38.3) |
Unless otherwise specified, data are mean ± standard deviation.
CGI-S, Clinical Global Impression of Severity; MAO-B, monoamine oxidase B; PDQ-8, short-form Parkinson's Disease Questionnaire; PDSS, Parkinson's Disease Sleep Scale; VAS, visual analogue scale.